Mbx Biosciences Inc 's Cash & cash equivalent grew by 77.99 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Mbx Biosciences Inc 's Quick Ratio to 33.1 a new company high.

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Quick Ratio than Mbx Biosciences Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 101, from total ranking in the first quarter 2026 at 110.

Explain Quick Ratio?
How much Cash & cash equivalents MBX�s has?
What are MBX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MBX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	101.26 %	38.98 %	42.42 %	10.46 %	99.69 %
Y / Y Cash & cash equivalent Change	248.19 %	82.73 %	42.55 %	41.37 %	178.6 %
Quick Ratio MRQ	33.1	30.2	24.12	32.47	19.13
MBX's Total Ranking	# 101	# 110	# 119	# 78	# 124
Seq. Current Liabilities Change	62.42 %	-5.99 %	28.46 %	2.6 %	12.16 %
Seq. Cash & cash equivalent Change	77.99 %	17.73 %	-4.59 %	74.15 %	-6.6 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 14
Healthcare Sector	# 20
Overall Market	# 101

Quick Ratio Statistics
High	Average	Low
33.1	25.02	13.71
(Jun 30 2026)		(Dec 31 2023)

Financial Statements
Mbx Biosciences Inc 's Current Liabilities	$ 24 Millions	Visit MBX's Balance sheet
Mbx Biosciences Inc 's Cash & cash equivalent	$ 783 Millions	Visit MBX's Balance sheet
Source of MBX's Sales		Visit MBX's Sales by Geography

Cumulative Mbx Biosciences Inc 's Quick Ratio

MBX's Quick Ratio for the trailling 12 Months

MBX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	49.38 %	41.17 %	79.85 %	168.81 %	648.04 %
Y / Y Cash & cash equivalent TTM Growth	97.88 %	66.17 %	98.58 %	212.9 %	1144.83 %
Quick Ratio TTM	30.23	26.55	24.72	24.78	22.82
Total Ranking TTM	# 2539	# 2646	# 1764	# 2214	# 2210
Seq. Current Liabilities TTM Growth	22.09 %	8.21 %	10.21 %	2.59 %	15.38 %
Seq. Cash & cash equivalent TTM Growth	39.03 %	16.18 %	9.96 %	11.41 %	16.75 %

Quick ratio ranking by company, industry and sector >> Back to MBX Financial Strength Comparisons >> Go to Compare MBX Quick Ratio to its Competitors

News about Mbx Biosciences Inc Quick Ratio

MBX Biosciences Advances Hypoparathyroidism Treatment with Successful Enrollment in Phase 2 Avail Trial of Canvuparat...

Advancement in Hypoparathyroidism Treatment: MBX Biosciences’ Phase 2 Avail Trial of MBX 2109 Concludes Enrollment MBX Biosciences has reached a significant milestone in the development of its promising treatment for hypoparathyroidism with the completion of participant enrollment in the Phase 2 Avail trial for MBX 2109, also known as Canvuparatide. With the number of enrollees surpassing the initial target, the trial is poised to provide crucial data that could potentially change the landscape of treatment for patients suffering from this challenging endocrine disorder. Topline results from the trial are anticipated in the third quarter of 2025. Understanding HypoparathyroidismHypoparathyroidism is a rare condition characterized by insufficient production of the parathyroid hormone (PTH), which plays a pivotal role in maintaining calcium and phosphorus balance in the body. This deficiency can lead to a variety of symptoms, including muscle cramps, tingling or burning sensations in the fingertips, toes, and lips, as well as more severe complications like cardiac arrhythmias and seizures. Current treatment options mainly focus on managing symptoms by supplementing calcium and vitamin D, but they do not address the underlying hormone deficiency.

On the trailing twelve months basis MBX Cash & cash equivalent more than doubled by 248.19 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Mbx Biosciences Inc 's Quick Ratio to 30.23, above MBX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 395 other companies have achieved higher Quick Ratio than Mbx Biosciences Inc . While Quick Ratio overall ranking has improved so far to 2539, from total ranking during the twelve months ending first quarter 2026 at 2646.

Explain Quick Ratio?
How much Cash & cash equivalents MBX�s has?
What are MBX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 396
Healthcare Sector	# 765
Within the Market	# 2539

trailing twelve months Quick Ratio Statistics
High	Average	Low
30.23	25.43	22.73
(Jun 30 2026)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Arca Biopharma Inc	87.05	$ 2,225.581 Millions	$ 25.566 Millions
Tango Therapeutics Inc	82.19	$ 1,668.432 Millions	$ 20.299 Millions
Contineum Therapeutics Inc	70.25	$ 458.440 Millions	$ 6.526 Millions
Sagimet Biosciences inc	61.23	$ 331.832 Millions	$ 5.419 Millions
Avalyn Pharma Inc	49.93	$ 539.733 Millions	$ 10.809 Millions
Pasithea Therapeutics Corp	49.76	$ 91.464 Millions	$ 1.838 Millions
Disc Medicine Inc	44.03	$ 1,336.770 Millions	$ 30.360 Millions
Trevi Therapeutics Inc	36.50	$ 318.870 Millions	$ 8.736 Millions
Design Therapeutics Inc	35.76	$ 401.889 Millions	$ 11.240 Millions
Mineralys Therapeutics Inc	34.87	$ 673.704 Millions	$ 19.319 Millions
Praxis Precision Medicines Inc	34.32	$ 1,683.790 Millions	$ 49.058 Millions
Agios Pharmaceuticals Inc	33.94	$ 2,383.112 Millions	$ 70.217 Millions
Mbx Biosciences Inc	33.10	$ 783.099 Millions	$ 23.660 Millions
Xbiotech Inc	32.67	$ 109.528 Millions	$ 3.353 Millions
Avalo Therapeutics Inc	31.89	$ 787.143 Millions	$ 24.682 Millions
Fulcrum Therapeutics Inc	30.96	$ 318.840 Millions	$ 10.298 Millions
Climb Bio Inc	30.86	$ 183.123 Millions	$ 5.934 Millions
Indaptus Therapeutics Inc	29.61	$ 15.554 Millions	$ 0.525 Millions
Crinetics Pharmaceuticals Inc	29.41	$ 2,350.275 Millions	$ 79.915 Millions
Spyre Therapeutics Inc	28.48	$ 1,100.000 Millions	$ 38.620 Millions
Curanex Pharmaceuticals Inc	28.17	$ 2.938 Millions	$ 0.104 Millions
Onkure Therapeutics Inc	28.04	$ 186.284 Millions	$ 6.643 Millions
Ligand Pharmaceuticals Incorporated	27.33	$ 1,277.438 Millions	$ 46.736 Millions
Shattuck Labs Inc	26.94	$ 208.300 Millions	$ 7.731 Millions
Cryoport inc	26.87	$ 785.860 Millions	$ 29.244 Millions
Roivant Sciences Ltd	26.82	$ 7,607.076 Millions	$ 283.603 Millions
Palvella Therapeutics Inc	26.23	$ 313.381 Millions	$ 11.947 Millions
Upstream Bio Inc	26.16	$ 261.307 Millions	$ 9.988 Millions
Rallybio Corporation	26.02	$ 92.800 Millions	$ 3.567 Millions
Assembly Biosciences Inc	25.95	$ 608.475 Millions	$ 23.445 Millions

Date modified: 2026-09-08T01:20:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.